NDAORALTABLET, DELAYED RELEASEPriority Review
Approved
Nov 2018
Lifecycle
Post-LOE
Competitive Pressure
35/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AEMCOLO (rifamycin sodium) is an oral delayed-release antibiotic tablet approved in 2018 for treating traveler's diarrhea caused by non-invasive strains of Escherichia coli. Rifamycin is a rifamycin-class antibiotic that acts locally in the gastrointestinal tract to reduce bacterial colonization. The delayed-release formulation ensures delivery to the target site while minimizing systemic absorption.
$0.006BPart D
Post-LOEPost-LOEPost-LOE status as of November 2023 signals a mature, smaller commercial footprint with limited team growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on AEMCOLO at Cosmo Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.